Benu's virtual play

New investment firm Benu BioVentures has the backing of a single investor to establish virtual companies that will develop preclinical programs and move them to Phase II proof of concept using an asset-centric model. Benu thinks its product development experience will allow it to compete with other firms and industry players hunting for preclinical assets.